0C0 Stock Chart & Stats
€0.27
<€0.01(1.94%)
At close: 4:00 PM EDT
€0.27
<€0.01(1.94%)
Day’s Range― - ―
52-Week Range€0.16 - €0.58
Previous CloseN/A
Volume0.00
Average Volume (3M)3.41K
Market Cap
€18.38M
Enterprise Value€20.73
Total Cash (Recent Filing)€4.37M
Total Debt (Recent Filing)€515.57K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding70,441,360
10 Day Avg. Volume2,290
30 Day Avg. Volume3,412
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€15.68M
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage reduces near-term balance-sheet pressure and preserves financial flexibility while the company develops its pipeline. Lower debt exposure can help management direct resources toward regulatory, research, and commercialization activities without heavy mandatory financing costs.
Improved Gross MarginA gross margin near 53% indicates the underlying technology may retain meaningful economics before operating expenses. If maintained as commercialization scales, this provides a foundation for operating leverage, although current losses show that revenue volume remains insufficient to support the broader cost base.
Asset-Light Commercialization ModelLicensing and royalty arrangements can provide a scalable route to market without requiring a large direct-to-farm distribution operation. Established partners may also support manufacturing, registration, and sales execution, allowing MustGrow to focus capital on technology development and regulatory progress.
Bears Say
Revenue ContractionThe sharp TTM revenue decline shows that commercial traction has not yet become consistent. Uneven top-line performance makes planning and funding more difficult, and it increases dependence on successful product approvals, partner execution, and future commercialization milestones to establish durable revenue growth.
Deep Operating LossesLarge operating and net losses indicate that current revenue is far below the level needed to cover the company’s cost structure and overhead. Unless scale improves materially or expenses are reduced, continuing losses can constrain investment capacity and weaken long-term shareholder returns.
Persistent Cash BurnSustained negative operating and free cash flow means the business is consuming rather than generating cash internally. This raises the likelihood that continued research, regulatory work, and commercialization efforts will require external funding, potentially limiting strategic flexibility if losses persist.
MustGrow Biologics News
0C0 FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was €0.16 and its highest was €0.58 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is €18.38M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Dec 01, 2026 which is in 70 days.
How were MustGrow Biologics’s earnings last quarter?
MustGrow Biologics released its earnings results on Aug 27, 2026. The company reported €0 earnings per share for the quarter.
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 70,441,360 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
MustGrow Biologics reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went down -7.586%.
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in DE:0C0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
0C0 Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―